RxDoctor Payments DataLook up a doctor →

Inhye Ahn, MD

Medical Oncology · Boston, MANPI 1053632984

Payments from drug & device makers

$9,844,895in general payments, 2019–2025

Across 70 payments — averaging $140,641 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pharmacyclics LLC, An Abbvie Company$4.7M
  • AbbVie$2.3M
  • Merck$1.9M
  • Lilly USA, LLC$469K
  • AstraZeneca$181K
  • Eli Lilly$94K
  • plus $208K from 4 others
$553,151in research payments, 2019–2025

Across 1 payment — averaging $553,151 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Lilly USA, LLC$553K

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pharmacyclics LLC, An Abbvie Company3$4,717,613
AbbVie3$2,297,997
Merck11$1,877,913
Lilly USA, LLC9$468,732
AstraZeneca4$180,895
Eli Lilly8$93,887
Beigene, Ltd.18$80,334
Beone Medicines USA, Inc.7$76,461
Beigene USA, Inc.6$51,043
Acacia Pharma Inc1$20

How this compares

$9,844,895 in reported general payments places this provider in the 90th percentile of 308 medical oncology providers in Massachusetts.

See all medical oncology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$44,901
Medicare patients
151
Services billed
355

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →